# Who Needs Access to Research? The Case of Pharmaceutical Industry

#### **ElHassan ElSabry**

Doctoral Student Science, Technology & Innovation Policy Program National Graduate Institute for Policy Studies (GRIPS)

> *Munin Conference November 21, 2016*

# Outline

- OA Usage beyond Academia
- Hypothesis
- Data Sources & Methodology
- Operational Variables
- Results
  - General Characteristics
  - Linear Regression
- Discussion
- Options for Future Research

## OA Usage beyond Academia

- Qualifying the assumption that making research articles openly accessible to everyone will have an impact beyond academia
- This kind of "spillover" is usually cited in policies advocating Open Access
- Very little (mainly anecdotal evidence) is available so far:
  - "Likewise, almost no studies have evaluated whether free access to the scientific literature has had an impact on the use of scientific information in non-research contexts such as teaching, medical practice, industry, and government." Davis et. al. (2011).

# Pharmaceutical Industry

- Science-intensive
- Small companies suffer
- Several data sources available for industry
- "One cannot expect high productivity from the smaller emerging companies that collectively suffer from an inability to afford access to reports describing new discoveries in the biomedical sciences." Lyman (2011)

# Hypotheses

- Main Hypothesis:
  - Smaller firms utilize OA articles more than large firms
- Control Parameters:
  - As more OA articles become available, firms use more of them.
  - The ratio of non-OA articles cited by patents is higher when the patent is co-owned with a university.
  - The ratio of OA articles cited by patents is higher if the company collaborates with other companies (owner/partner)
  - The ratio of OA articles cited by patents is higher if the patented technology is not pharmaceutical

#### Data Sources



Company information and business intelligence



DIRECTORY OF **OPEN ACCESS** JOURNALS



# Methodology

- 1. Collecting company financial data (those with A61K patents)
- 2. Matching patent data (grant date, collaborators, NPL citations)
- 3. Matching patent years with OA movement indicators
- 4. Running a Linear Regression to test hypotheses
- 5. Identifying patterns in company's access to scientific literature

#### Patent FrontPage

(56)

EP

#### (12) United States Patent Brune et al.

(10) Patent No.:US 8,927,231 B2(45) Date of Patent:Jan. 6, 2015

(54) SEPARATOME-BASED PROTEIN EXPRESSION AND PURIFICATION PLATFORM

- (71) Applicants: Board of Trustees of the University of Arkansas, Little Rock, AR (US); University of Pittsburgh—Of The Commonwealth System of Higher Education, Pittsburgh, PA (US)
- Inventors: Ellen M. Brune, Fayetteville, AR (US);
  Robert R. Beitle, Jr., Fayetteville, AR (US); Mohammad M. Ataai, Pittsburgh, PA (US); Patrick R. Bartlow, Pittsburgh, PA (US); Ralph L. Henry, Little Rock, AR (US)
- (73) Assignees: The Board of Trustees of the University of Arkansas, Little Rock, AK (US); University of Pittsburgh—Of The Commonwealth System of Higher Education, Pittsburgh, PA (US)
- (\*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.
- (21) Appl. No.: 14/056,747

U.S. PATENT DOCUMENTS 1/2006 Blattner et al. 6.989.265 B2 7.303.906 B2 12/2007 Blattner et al. 8.039.243 B2 10/2011 Blattner 8.043.842 B2 10/2011 Blattner et al. 8.119.365 B2 2/2012 Blattner et al. 8,178,339 B2 5/2012 Campbell et al. 8.697.359 B1 4/2014 Zhang 2009/0075333 A1\* 3/2009 Campbell et al. ..... 435/69.1 3/2009 Lee et al. 2009/0075352 A1 2012/0183995 A1 7/2012 Ferrari et al. 8/2012 Blattner et al. 2012/0219994 A1

**References** Cited

**FOREIGN PATENT DOCUMENTS** 

1483367 B1 5/2010

Amrein et al., "Purification and characterization of recombinant human p50csk protein-tyrosine kinase from an *Escherichia coli* expresion system overproducing the bacterial chaperones GroES and GroEL" 92 Proceedings of the National Academy of Sciences USA 1048-1049 (1995).\*

Shin et al., "Extracellular Recombinant Protein Production From an *Escherichia coli* Ipp Deletion Mutant" 101(6) Biotechnoloogy and Bioengineering 1288-1296 (2008).\*

Posfai et al., "Emergent Properties of Reduced-Genome Escherichia coli" 312 Science 1044-1046 (2006).\*


Yu et al. (2002) Nature Biotechnol. 20:1018-1023. Agania et al. (2004) Journal of Molecular Percentition 17:236-247

#### Non-Patent Literature

#### (NPL)

- journal articles
- search reports
- GeneBank records
- Company reports
- etc.

### Regression Variables




# **Operational Definitions**

| Variable of Interest                | Corresponding Indicator   |
|-------------------------------------|---|
| Using Open Access                   | citations to OA journals / all journals in non-patent citations         |
| Company Size                        | turnover in USD (1 year before patent grant)                            |
| Company Size                        | number of employees (1 year before patent grant)                        |
| Company Technological<br>Capability | total number of patent <u>documents</u> affiliated with the company     |
| Patent Relevance                    | whether the patent is classified under A61, C07,C08,C12 (CPC)           |
| University Collaborator             | whether the company co-owns the patent with a university                |
| Company Collaborator                | whether the company co-owns the patent with another company             |
| OA Availability                     | total number of DOAJ-listed journals (1 year before patent grant)       |
| OA Awareness                        | total number of ROARMAP-listed OA mandates (1 year before patent grant) |

# Results (general)

| Description   | Company<br>Count | Patent<br>Count | Citation<br>Count |
|---|------------------|-----------------|-------------------|
| All US Pharmaceutical Companies (excluding "very large")  | 1447             | 13534           |                   |
| with US-registered patents between 2006 & 2015            | 654              | 9221            |                   |
| with matching financial data (1 year before patent grant) | 354              | 1104            | 39037             |
| that cite academic journals                               | 280              | 825             | 28694             |
| that cite Open Access journals                            | 193              | 483             | 2177              |



# Results (regression)

|               | Coefficients | Standard Error | P-value     |
|---------------|--------------|----------------|-------------|
| Intercept     | 0.079528052  | 0.025225871    | 0.001677255 |
| TurnoverUSDk  | 2.2716E-07   | 2.51463E-07    | 0.366604681 |
| EmployeeCount | -8.57876E-05 | 4.55324E-05    | 0.059906983 |
| GroupMember   | 0.003140609  | 0.033034095    | 0.924281221 |
| RelatedClass  | -0.001255594 | 0.020145863    | 0.950319173 |
| PatentCount   | -1.99357E-05 | 3.66052E-05    | 0.586167188 |
| UnivCollab    | -0.066499863 | 0.025620465    | 0.009613161 |
| CompCollab    | 0.047283091  | 0.030029228    | 0.115744051 |
| DOAJ          | 3.86958E-06  | 1.17576E-05    | 0.742155218 |
| ROARMAP       | 3.30392E-05  | 0.000169614    | 0.845605189 |

| Regression St     | tatistics   |   |
|-------------------|-------------|---|
| Multiple R        | 0.150487186 |   |
| R Square          | 0.022646393 |   |
| Adjusted R Square | 0.011853531 | Dependent Variable                        |
| Standard Error    | 0.167804525 | OA Ratio = OA Count / Total Journal Count |
| Observations      | 825         | •   |

|               | Coefficients | Standard Error | P-value  |
|---------------|--------------|----------------|----------|
| Intercept     | 0.754997     | 1.073173       | 0.481933 |
| TurnoverUSDk  | -3.5E-06     | 1.07E-05       | 0.745808 |
| EmployeeCount | -0.00121     | 0.001937       | 0.533298 |
| GroupMember   | -1.47545     | 1.405354       | 0.294087 |
| RelatedClass  | 0.893461     | 0.857056       | 0.2975   |
| PatentCount   | -0.00203     | 0.001557       | 0.192006 |
| UnivCollab    | -0.79038     | 1.08996        | 0.46857  |
| CompCollab    | 0.272973     | 1.27752        | 0.830855 |
| DOAJ          | 0.000332     | 0.0005         | 0.506531 |
| ROARMAP       | 0.000828     | 0.007216       | 0.908621 |

| <b>Regression Statistics</b> |          |  |  |
|------------------------------|----------|--|--|
| Multiple R                   | 0.144167 |  |  |
| R Square                     | 0.020784 |  |  |
| Adjusted R Square            | 0.009971 |  |  |
| Standard Error               | 7.138832 |  |  |
| Observations                 | 825      |  |  |

Dependent Variable
OA Count

## Results (regression, OA only)

|               | Coefficients | Standard Error | P-value  |
|---------------|--------------|----------------|----------|
| Intercept     | 0.303528     | 0.04541        | 6.55E-11 |
| TurnoverUSDk  | 2.21E-07     | 3.62E-07       | 0.540544 |
| EmployeeCount | -0.00013     | 6.69E-05       | 0.04881  |
| GroupMember   | 0.049552     | 0.052425       | 0.345042 |
| RelatedClass  | -0.1439      | 0.038112       | 0.00018  |
| PatentCount   | 1.52E-05     | 7.17E-05       | 0.832727 |
| UnivCollab    | -0.10512     | 0.038645       | 0.006767 |
| CompCollab    | 0.08597      | 0.043991       | 0.051258 |
| DOAJ          | 2.77E-05     | 1.91E-05       | 0.14808  |
| ROARMAP       | -0.00033     | 0.000282       | 0.23778  |

|               | Coefficients | Standard Error | P-value  |
|---------------|--------------|----------------|----------|
| Intercept     | 5.31197      | 2.115285       | 0.012363 |
| TurnoverUSDk  | -6.6E-06     | 1.68E-05       | 0.694977 |
| EmployeeCount | -0.00184     | 0.003115       | 0.555868 |
| GroupMember   | -1.4023      | 2.442073       | 0.566089 |
| RelatedClass  | -1.64438     | 1.775337       | 0.354795 |
| PatentCount   | -0.00432     | 0.003342       | 0.196581 |
| UnivCollab    | -1.04411     | 1.800157       | 0.562182 |
| CompCollab    | 0.494459     | 2.049197       | 0.809432 |
| DOAJ          | 0.000966     | 0.00089        | 0.278144 |
| ROARMAP       | -0.00734     | 0.013133       | 0.576376 |


| Regression Statistics               |                          |  |
|-------------------------------------|--------------------------|--|
| Multiple R                          | 0.266549                 |  |
| R Square                            | 0.071048                 |  |
|                                     |                          |  |
| Adjusted R Square                   | 0.053373                 |  |
| Adjusted R Square<br>Standard Error | <b>0.053373</b> 0.190322 |  |

| Dependent Variable                        |
|---|
| OA Ratio = OA Count / Total Journal Count |

| Regression Statistics |          |  |
|-----------------------|----------|--|
| Multiple R            | 0.174752 |  |
| R Square              | 0.030538 |  |
| Adjusted R Square     | 0.012092 |  |
| Standard Error        | 8.865642 |  |
|                       | 0.000012 |  |


# Dependent Variable OA Count

# Number of Citations to OA Journals



- Average annual increase of 38%
- Compared to 16% for Journal citations in general

# Number of Patents Citing OA Journals



- Average annual increase of 22%
- Compared to 15% for patents citing journals in general

### Discussion

- Underestimation due to disregarding green & hybrid OA
- relative short age of OA journals
- OA journals gaining ground in patent citations
- sample bias to companies with financial data
- importance of abstracts for patents / need for more OA

## **Options for Future Research**

- suggestions for further manipulation??
- including hybrid & green OA
- focus on later years only
- matching with PubMed Central records

# Thank You